https://www.selleckchem.com/pr....oducts/sorafenib.htm
001) children who were younger or of smaller body size had lower CL/F; however, age and body size did not appear to negatively affect safety or efficacy response to plasma drug exposure. Based on PK, safety, and efficacy trial simulations, a sunitinib starting dose of ~ 25mg/m /day was predicted to provide comparable plasma drug exposures in children with GIST as in adults with GIST treated with 50mg/day. However, in the absence of a tumor type effect of sunitinib on CL/F in children, the projected equivalent dose for this population
Beğen
Yorum Yap
Paylaş
